BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Partners with Leading Medical Imaging Group for Upcoming Berubicin Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has announced that it will partner with Image Analysis Group (“IAG”) for planned Berubicin clinical trials. IAG, a leading medical imaging group, and CNS will work together to provide critical imaging services and imaging data analysis for the trials. IAG has an extensive background of partnering with oncology companies to deliver centralized readings and analysis of patient responses in real time. IAG’s expertise will allow CNS to review efficacy assessments and explore the advanced-treatment manifestations. Because GBM therapies often lead to pseudo-progression that is commonly mistaken as tumor growth, this partnership is key. The clinical trials will be utilizing IAG’s advanced artificial intelligence (“AI”)-driven methodologies to produce reliable early efficacy readouts. “Adding IAG was a key step in preparation for the recently developed clinical trials in Berubicin,” said CNS Pharmaceuticals CEO John Climaco in the press release. “IAG has an exemplary track record of partnering closely with companies in the biotech space to provide critical analysis of both efficacy and patient response, which we believe will be pivotal in advancing our Berubicin clinical trials. Furthermore, this was yet another key milestone achieved in our trial preparations as we continue to take all of the necessary steps to ensure a successful and timely launch of our Phase II trials. We look forward to leveraging IAG’s extensive expertise, as we plan to initiate our Phase II clinical trial of Berubicin in adults early next year.”

To view the full press release, visit https://ibn.fm/EQvO3

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the United States, while a sublicensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. The company’s second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies to be 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at https://cnspharma.com/.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

More News From The World Agenda

Stocks rise as China confirms trade deal signing next week

Oct 29, 2020

NEW YORK — U.S stocks climbed in morning trading on Thursday as investors cheered confirmation from China that its top trade official will head to Washington next week to sign a preliminary trade deal. The “Phase 1” accord is the opening step on a possible path toward a broader agreement between the nations. President Donald Trump has said he will travel to Beijing after the initial signing to start the second stage of talks. Every major index is on track for a record as Wall Street distances itself from a bout of anxiety over the last week because of tensions...

Counting whales from space pitched as key to saving them

Oct 29, 2020

PORTLAND, Maine — An aquarium and an engineering firm in Massachusetts are partnering on a project to better protect whales by monitoring them from space. New England Aquarium of Boston and Draper of Cambridge say whale conservation needs new, higher-tech solutions to protect whales from extinction. So, the pair is working together using data from sources such as satellites, sonar and radar to keep a closer eye on how many whales are in the ocean. The effort has an easy to understand name for a project involving complex data and surveillance — the aquarium and firm are calling the project...

US heads to court to build Trump border wall in Texas

Oct 29, 2020

HOUSTON — Three years into Donald Trump's presidency, the U.S. government is ramping up its efforts to seize private land in Texas to build a border wall. Trump's signature campaign promise has consistently faced political, legal, and environmental obstacles in Texas, which has the largest section of the U.S.-Mexico border, most of it without fencing. And much of the land along the Rio Grande, the river that forms the border in Texas, is privately held and environmentally sensitive. Almost no land has been taken so far. But Department of Justice lawyers have filed three lawsuits this month seeking to take...

Space Force will start small but let Trump claim a big win

Oct 29, 2020

WASHINGTON — The Trump administration is celebrating the launch of Space Force, the first new military service in more than 70 years. In signing the 2020 National Defense Authorization Act that includes Space Force, Trump on Friday can claim a victory for one of his top national security priorities just two days after being impeached by the House. It is part of a $1.4 trillion government spending package — including the Pentagon's budget — that provides a steady stream of financing for Trump's U.S.-Mexico border fence and reverses unpopular and unworkable automatic spending cuts to defense and domestic programs. Space...

House passes $1.4T government spending bill amid impeachment

Oct 29, 2020

WASHINGTON — The Democratic-controlled House voted Tuesday to pass a $1.4 trillion government spending package, handing President Donald Trump a victory on his U.S.-Mexico border fence while giving Democrats spending increases across a swath of domestic programs. The hard-fought legislation also funds a record Pentagon budget and is serving as a must-pass legislative locomotive to tow an unusually large haul of unrelated provisions into law, including an expensive repeal of Obama-era taxes on high-cost health plans, help for retired coal miners, and an increase from 18 to 21 in the nationwide legal age to buy tobacco products. The two-bill package,...

Here at The World Agenda, we bring innovation to digital news for you to keep abreast of worldwide news instantly anywhere.

Contact us: sales[at]theworldagenda.com